Celularity Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Celularity Inc. on December 5, 2025, reporting an event that occurred on December 1, 2025. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Florham Park, New Jersey. Its Class A Common Stock (CELU) and Warrants (CELUW) trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory event rather than financial performance data.
Material Changes and Regulatory Event
On December 1, 2025, the Company received a warning letter from the U.S. Food and Drug Administration (FDA) regarding marketing materials for its product, Interfyl (a human connective tissue matrix). The FDA indicated that to market the product consistent with its 2004 Request for Designation, the Company must limit the use of outcome-based claims and claims regarding metabolic activity within the body.
- The letter does not restrict the Company's ability to manufacture or ship products.
- No product recall is required.
- The Company's ability to seek FDA 510(k) clearance for products is not restricted.
Management Commentary, Risks, and Outlook
Management states it takes the matters identified in the letter seriously and is committed to working with the FDA to resolve them. The Company is not aware of any additional actions stemming from the letter that will have a material impact on previously announced operational or financial expectations. However, the Company cannot assure that the FDA will be satisfied with its response or provide an expected date for resolution. Until resolved, additional regulatory action may be taken without further notice.
Investor Verification Checklist
- Verify the specific marketing claims identified in the FDA warning letter that require remediation.
- Monitor for any follow-up correspondence or enforcement actions from the FDA regarding Interfyl.
- Confirm the timeline for the Company's response to the FDA and the status of the 510(k) clearance process.
- Review subsequent filings for any updates on the resolution of the regulatory matter.